GLORIA VERTIN: Open Payments
NPI 1851901623 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$249 in 15 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $249
Food & beverage: $249
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $50 |
| Lilly USA, LLC | 3 | $47 |
| Amgen Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| GlaxoSmithKline, LLC. | 2 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| ABBVIE INC. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: MOUNJARO, Ozempic, Auvelity, SHINGRIX, BREZTRI, REPATHA, Wegovy, UBRELVY.
Industry payments across TX — which companies pay providers there.
